<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="8" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font3" size="7" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font4" size="9" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font5" size="9" family="SymbolMT" color="#000000"/>
	<fontspec id="font6" size="9" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font7" size="9" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font8" size="11" family="AkzidenzGroteskBE,Bold" color="#000000"/>
<text top="42" left="315" width="241" height="7" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="text">Available online http://breast-cancer-research.com/content/8/5/R56<b>Available online</b></text>
<text top="758" left="511" width="45" height="7" font="font2" id="p1_t2" reading_order_no="105" segment_no="11" tag_type="text">Page 5 of 15</text>
<text top="769" left="436" width="120" height="6" font="font3" id="p1_t3" reading_order_no="106" segment_no="12" tag_type="text">(page number not for citation purposes)</text>
<text top="82" left="57" width="241" height="12" font="font4" id="p1_t4" reading_order_no="1" segment_no="1" tag_type="text">was used per 30 µ l PCR. RT-PCR was performed by using the<i>(page number not for citation purposes)</i></text>
<text top="97" left="57" width="240" height="9" font="font4" id="p1_t5" reading_order_no="2" segment_no="1" tag_type="text">Applied Biosystems AmpliTaq Gold, Cheshire, UK, with either</text>
<text top="109" left="57" width="240" height="9" font="font4" id="p1_t6" reading_order_no="3" segment_no="1" tag_type="text">25 or 30 cycles, each consisting of 30 s at 94°C, 30 s at</text>
<text top="120" left="57" width="240" height="9" font="font4" id="p1_t7" reading_order_no="4" segment_no="1" tag_type="text">55°C, and 45 s at 72°C. PCR products were visualised on 2%</text>
<text top="132" left="57" width="240" height="9" font="font4" id="p1_t8" reading_order_no="5" segment_no="1" tag_type="text">Invitrogen agarose E-Gels 96 Gels (Invitrogen Life Technolo-</text>
<text top="144" left="57" width="102" height="9" font="font4" id="p1_t9" reading_order_no="6" segment_no="1" tag_type="text">gies, Carlsbad, CA, USA).</text>
<text top="167" left="57" width="231" height="8" font="font6" id="p1_t10" reading_order_no="7" segment_no="5" tag_type="title">Immunohistochemistry and tissue microarray analysis</text>
<text top="179" left="57" width="240" height="9" font="font4" id="p1_t11" reading_order_no="8" segment_no="7" tag_type="text">A cohort of invasive breast carcinomas from 245 patients</text>
<text top="191" left="57" width="240" height="9" font="font4" id="p1_t12" reading_order_no="9" segment_no="7" tag_type="text">treated with surgery (wide local excision or mastectomy) and</text>
<text top="203" left="57" width="240" height="9" font="font4" id="p1_t13" reading_order_no="10" segment_no="7" tag_type="text">adjuvant anthracycline-based chemotherapy was retrieved<b>Immunohistochemistry and tissue microarray analysis</b></text>
<text top="214" left="57" width="240" height="9" font="font4" id="p1_t14" reading_order_no="11" segment_no="7" tag_type="text">from the Department of Histopathology files of the Royal</text>
<text top="226" left="57" width="240" height="9" font="font4" id="p1_t15" reading_order_no="12" segment_no="7" tag_type="text">Marsden Hospital (London, UK) with appropriate local Ethical</text>
<text top="238" left="57" width="240" height="9" font="font4" id="p1_t16" reading_order_no="13" segment_no="7" tag_type="text">Committee approval. Representative blocks were reviewed by</text>
<text top="250" left="57" width="240" height="9" font="font4" id="p1_t17" reading_order_no="14" segment_no="7" tag_type="text">a pathologist (JSRF) and selected cores were incorporated in</text>
<text top="261" left="57" width="240" height="9" font="font4" id="p1_t18" reading_order_no="15" segment_no="7" tag_type="text">two duplicate tissue microarray (TMA) blocks [32,33]. Full</text>
<text top="273" left="57" width="240" height="9" font="font4" id="p1_t19" reading_order_no="16" segment_no="7" tag_type="text">details of the TMA are given as Additional file 3. TMA samples</text>
<text top="285" left="57" width="240" height="9" font="font4" id="p1_t20" reading_order_no="17" segment_no="7" tag_type="text">were dewaxed in xylene, cleared in absolute ethanol and</text>
<text top="297" left="57" width="240" height="9" font="font4" id="p1_t21" reading_order_no="18" segment_no="7" tag_type="text">blocked in methanol for 10 minutes. Antigen retrieval for carti-<a href="">[32,33]</a>. Full</text>
<text top="308" left="57" width="240" height="9" font="font4" id="p1_t22" reading_order_no="19" segment_no="7" tag_type="text">lage oligomeric matrix protein (COMP) and IL8 was by boiling</text>
<text top="320" left="57" width="240" height="9" font="font4" id="p1_t23" reading_order_no="20" segment_no="7" tag_type="text">slides in citrate buffer (pH 6) for 2 minutes in a pressure</text>
<text top="332" left="57" width="240" height="9" font="font4" id="p1_t24" reading_order_no="21" segment_no="7" tag_type="text">cooker, after which they were blocked with normal horse</text>
<text top="344" left="57" width="240" height="9" font="font4" id="p1_t25" reading_order_no="22" segment_no="7" tag_type="text">serum (2.5% for 20 minutes; Vector Laboratories VL, Burlin-</text>
<text top="355" left="57" width="240" height="9" font="font4" id="p1_t26" reading_order_no="23" segment_no="7" tag_type="text">game, CA, USA) and endogenous biotin blocked by pre-incu-</text>
<text top="367" left="57" width="240" height="9" font="font4" id="p1_t27" reading_order_no="24" segment_no="7" tag_type="text">bating with avidin (15 minutes) and biotin (15 minutes). They</text>
<text top="379" left="57" width="240" height="9" font="font4" id="p1_t28" reading_order_no="25" segment_no="7" tag_type="text">were then incubated with anti-COMP antibody (1/50; Sero-</text>
<text top="391" left="57" width="240" height="9" font="font4" id="p1_t29" reading_order_no="26" segment_no="7" tag_type="text">tec, Oxford, UK) or IL8 antibody (1/5; Serotec) for 1 h at room</text>
<text top="402" left="57" width="240" height="9" font="font4" id="p1_t30" reading_order_no="27" segment_no="7" tag_type="text">temperature. For immunohistochemistry of Periostin (POSTN),</text>
<text top="414" left="57" width="240" height="9" font="font4" id="p1_t31" reading_order_no="28" segment_no="7" tag_type="text">sections were pretreated by microwaving in Dakocytomation</text>
<text top="426" left="57" width="240" height="9" font="font4" id="p1_t32" reading_order_no="29" segment_no="7" tag_type="text">(Glostrup, Denmark) pH 6 antigen retrieval buffer for 18 min-</text>
<text top="438" left="57" width="240" height="9" font="font4" id="p1_t33" reading_order_no="30" segment_no="7" tag_type="text">utes, blocked, and anti-POSTN antibody (1/1500; Biovendor</text>
<text top="449" left="57" width="240" height="9" font="font4" id="p1_t34" reading_order_no="31" segment_no="7" tag_type="text">Laboratory, Heidelberg, Germany) applied for 30 minutes at</text>
<text top="461" left="57" width="240" height="9" font="font4" id="p1_t35" reading_order_no="32" segment_no="7" tag_type="text">room temperature. Antibody binding was detected using</text>
<text top="473" left="57" width="240" height="9" font="font4" id="p1_t36" reading_order_no="33" segment_no="7" tag_type="text">Vectastain Universal ABC (VL), visualised with 3,3'-diami-</text>
<text top="485" left="57" width="240" height="9" font="font4" id="p1_t37" reading_order_no="34" segment_no="7" tag_type="text">nobenzidine DAKO (Corporation, Glostrup, Denmark). Full</text>
<text top="496" left="57" width="240" height="9" font="font4" id="p1_t38" reading_order_no="35" segment_no="7" tag_type="text">details on the distribution of ER, PR, HER2, EGFR, CK 14, CK</text>
<text top="508" left="57" width="240" height="9" font="font4" id="p1_t39" reading_order_no="36" segment_no="7" tag_type="text">5/6, and CK 17, as well as P53 (DO7, 1/200; DAKO Corpo-</text>
<text top="520" left="57" width="240" height="9" font="font4" id="p1_t40" reading_order_no="37" segment_no="7" tag_type="text">ration) are described elsewhere [33] and summarised in Addi-</text>
<text top="532" left="57" width="240" height="9" font="font4" id="p1_t41" reading_order_no="38" segment_no="7" tag_type="text">tional file 3. To evaluate the proliferative activity of tumour cells,</text>
<text top="543" left="57" width="240" height="9" font="font4" id="p1_t42" reading_order_no="39" segment_no="7" tag_type="text">immunohistochemical detection of MIB1 antibody to detect Ki-</text>
<text top="555" left="57" width="240" height="9" font="font4" id="p1_t43" reading_order_no="40" segment_no="7" tag_type="text">67 nuclear antigen (1/300; DAKO Corporation), which is<a href="">[33] and </a>summarised in Addi-</text>
<text top="567" left="57" width="240" height="9" font="font4" id="p1_t44" reading_order_no="41" segment_no="7" tag_type="text">associated with cell proliferation, was carried out under the</text>
<text top="579" left="57" width="240" height="9" font="font4" id="p1_t45" reading_order_no="42" segment_no="7" tag_type="text">same conditions [33]. For these markers, only nuclear staining</text>
<text top="590" left="57" width="241" height="9" font="font4" id="p1_t46" reading_order_no="43" segment_no="7" tag_type="text">was considered specific. Ki67 (MIB1) staining was scored low</text>
<text top="602" left="57" width="240" height="9" font="font4" id="p1_t47" reading_order_no="44" segment_no="7" tag_type="text">if less than 10% of neoplastic cells were positive, intermediate</text>
<text top="614" left="57" width="240" height="9" font="font4" id="p1_t48" reading_order_no="45" segment_no="7" tag_type="text">if 10% to 30% of neoplastic cells were positive and high if<a href="">33]</a>. For these markers, only nuclear staining</text>
<text top="626" left="57" width="240" height="9" font="font4" id="p1_t49" reading_order_no="46" segment_no="7" tag_type="text">more  than  30%  of  neoplastic  cells  were  positive  [32].</text>
<text top="637" left="57" width="240" height="9" font="font4" id="p1_t50" reading_order_no="47" segment_no="7" tag_type="text">Tumours were scored positive for P53 if &gt;10% of the nuclei of</text>
<text top="649" left="57" width="182" height="9" font="font4" id="p1_t51" reading_order_no="48" segment_no="7" tag_type="text">neoplastic cells displayed strong staining [32].</text>
<text top="673" left="57" width="240" height="9" font="font4" id="p1_t52" reading_order_no="49" segment_no="10" tag_type="text">Cumulative survival probabilities were calculated using the<a href="">[32</a>].</text>
<text top="684" left="57" width="240" height="9" font="font4" id="p1_t53" reading_order_no="50" segment_no="10" tag_type="text">Kaplan-Meier method/log-rank test. Differences between dis-</text>
<text top="696" left="57" width="240" height="9" font="font4" id="p1_t54" reading_order_no="51" segment_no="10" tag_type="text">ease-free interval and survival were tested with the log-rank<a href="">strong staining [32].</a></text>
<text top="708" left="57" width="240" height="9" font="font4" id="p1_t55" reading_order_no="52" segment_no="10" tag_type="text">test (two-tailed, confidence interval 95%) using the statistical</text>
<text top="720" left="57" width="240" height="9" font="font4" id="p1_t56" reading_order_no="53" segment_no="10" tag_type="text">software Statview 5.0., NC, USA. Multivariate analysis was</text>
<text top="85" left="315" width="241" height="9" font="font4" id="p1_t57" reading_order_no="54" segment_no="2" tag_type="text">performed using the Cox multiple hazards model. A P value &lt;</text>
<text top="97" left="315" width="240" height="9" font="font4" id="p1_t58" reading_order_no="55" segment_no="2" tag_type="text">0.05 in the univariate survival analysis was used as the limit for</text>
<text top="109" left="315" width="134" height="9" font="font4" id="p1_t59" reading_order_no="56" segment_no="2" tag_type="text">inclusion in the multivariate model.</text>
<text top="132" left="315" width="39" height="10" font="font8" id="p1_t60" reading_order_no="57" segment_no="3" tag_type="title">Results</text>
<text top="144" left="315" width="239" height="8" font="font6" id="p1_t61" reading_order_no="58" segment_no="4" tag_type="title">MPSS analysis of normal luminal and malignant breast<i>P </i></text>
<text top="156" left="315" width="50" height="8" font="font6" id="p1_t62" reading_order_no="59" segment_no="4" tag_type="title">cancer cells</text>
<text top="167" left="315" width="240" height="9" font="font4" id="p1_t63" reading_order_no="60" segment_no="6" tag_type="text">The gene expression profiles that were obtained by MPSS</text>
<text top="179" left="315" width="240" height="9" font="font4" id="p1_t64" reading_order_no="61" segment_no="6" tag_type="text">analysis yielded 24,288 and 28,404 signature sequences for</text>
<text top="191" left="315" width="240" height="9" font="font4" id="p1_t65" reading_order_no="62" segment_no="6" tag_type="text">the malignant and the normal breast epithelium, respectively;<b>Results</b></text>
<text top="203" left="315" width="240" height="9" font="font4" id="p1_t66" reading_order_no="63" segment_no="6" tag_type="text">these were pared down to the 'signature-centric' version con-<b>MPSS analysis of normal luminal and malignant breast </b></text>
<text top="214" left="315" width="240" height="9" font="font4" id="p1_t67" reading_order_no="64" segment_no="6" tag_type="text">taining 14,245 uniquely mapped and expressed transcripts for<b>cancer cells</b></text>
<text top="226" left="315" width="241" height="9" font="font4" id="p1_t68" reading_order_no="65" segment_no="6" tag_type="text">the malignant sample and 10,249 transcripts for the normal</text>
<text top="238" left="315" width="240" height="9" font="font4" id="p1_t69" reading_order_no="66" segment_no="6" tag_type="text">luminal epithelial sample (Table 1). Based on our HTR</text>
<text top="250" left="315" width="241" height="9" font="font4" id="p1_t70" reading_order_no="67" segment_no="6" tag_type="text">(described in Materials and methods [21]), these transcripts</text>
<text top="261" left="315" width="241" height="9" font="font4" id="p1_t71" reading_order_no="68" segment_no="6" tag_type="text">corresponded to 8,421 and 6,477 HTR clusters in the malig-</text>
<text top="273" left="315" width="240" height="9" font="font4" id="p1_t72" reading_order_no="69" segment_no="6" tag_type="text">nant and the normal RNA samples, respectively (Table 1), of</text>
<text top="285" left="315" width="240" height="9" font="font4" id="p1_t73" reading_order_no="70" segment_no="6" tag_type="text">which 3,191 genes were uniquely expressed in the malignant</text>
<text top="297" left="315" width="240" height="9" font="font4" id="p1_t74" reading_order_no="71" segment_no="6" tag_type="text">sample, and 1,297 in the normal sample. To define differential<a href="">able 1). Based </a>on our HTR</text>
<text top="308" left="315" width="240" height="9" font="font4" id="p1_t75" reading_order_no="72" segment_no="6" tag_type="text">expression, a comparative Poisson test was applied [34] and<a href="">ods [21]),</a> these transcripts</text>
<text top="320" left="315" width="241" height="9" font="font4" id="p1_t76" reading_order_no="73" segment_no="6" tag_type="text">6,553 genes were identified that showed a differential expres-</text>
<text top="329" left="315" width="240" height="12" font="font4" id="p1_t77" reading_order_no="74" segment_no="6" tag_type="text">sion measurement with P ≤ 0.05. (Raw and annotated MPSS<a href=""> 1)</a>, of</text>
<text top="344" left="315" width="240" height="9" font="font4" id="p1_t78" reading_order_no="75" segment_no="6" tag_type="text">data are provided as Additional file 4) Expression levels of dif-</text>
<text top="355" left="315" width="240" height="9" font="font4" id="p1_t79" reading_order_no="76" segment_no="6" tag_type="text">ferentially upregulated transcripts in the tumour sample</text>
<text top="367" left="315" width="241" height="9" font="font4" id="p1_t80" reading_order_no="77" segment_no="6" tag_type="text">ranged from less than 10 tpm ( ESR1 , EGF , GPR150 ,<a href="">n test was applied [34] and</a></text>
<text top="379" left="315" width="241" height="9" font="font7" id="p1_t81" reading_order_no="78" segment_no="6" tag_type="text">GADD45BGIP1 ), to over 1,000 tpm ( COL1A1 , SCGB2A2 ,</text>
<text top="391" left="315" width="46" height="9" font="font7" id="p1_t82" reading_order_no="79" segment_no="6" tag_type="text">SELE , IL8 ).</text>
<text top="414" left="315" width="214" height="8" font="font6" id="p1_t83" reading_order_no="80" segment_no="8" tag_type="title">Establishing a microarray validated transcriptome<i>P </i></text>
<text top="426" left="315" width="240" height="9" font="font4" id="p1_t84" reading_order_no="81" segment_no="9" tag_type="text">The MPSS derived transcriptomes were compared with gene</text>
<text top="438" left="315" width="240" height="9" font="font4" id="p1_t85" reading_order_no="82" segment_no="9" tag_type="text">expression profiles of the same RNA pools obtained using</text>
<text top="449" left="315" width="240" height="9" font="font4" id="p1_t86" reading_order_no="83" segment_no="9" tag_type="text">three oligonucleotide genome-wide microarrays, Affymetrix</text>
<text top="461" left="315" width="241" height="9" font="font4" id="p1_t87" reading_order_no="84" segment_no="9" tag_type="text">U133 Plus 2.0 GeneChip and CodeLink™ Human Whole</text>
<text top="473" left="315" width="241" height="9" font="font4" id="p1_t88" reading_order_no="85" segment_no="9" tag_type="text">Genome Bioarray, Agilent Whole Human Genome Oligo</text>
<text top="485" left="315" width="241" height="9" font="font4" id="p1_t89" reading_order_no="86" segment_no="9" tag_type="text">Microarray 44 k cDNA array and 20 k brk cDNA microarray.<i>ESR1</i></text>
<text top="496" left="315" width="240" height="9" font="font4" id="p1_t90" reading_order_no="87" segment_no="9" tag_type="text">These different microarray platforms were chosen to achieve</text>
<text top="508" left="315" width="240" height="9" font="font4" id="p1_t91" reading_order_no="88" segment_no="9" tag_type="text">the highest possible coverage of known transcribed<i>EGF</i></text>
<text top="520" left="315" width="240" height="9" font="font4" id="p1_t92" reading_order_no="89" segment_no="9" tag_type="text">sequences. Features from all platforms were mapped to HTR</text>
<text top="532" left="315" width="240" height="9" font="font4" id="p1_t93" reading_order_no="90" segment_no="9" tag_type="text">clusters and our analysis was restricted to those that mapped<i>GPR150</i></text>
<text top="543" left="315" width="240" height="9" font="font4" id="p1_t94" reading_order_no="91" segment_no="9" tag_type="text">unambiguously to one HTR cluster. For the Affymetrix platform</text>
<text top="555" left="315" width="241" height="9" font="font4" id="p1_t95" reading_order_no="92" segment_no="9" tag_type="text">41,322 of 54,613 (75.66%) features could be assigned to<i>GADD45BGIP1</i></text>
<text top="567" left="315" width="240" height="9" font="font4" id="p1_t96" reading_order_no="93" segment_no="9" tag_type="text">unique HTR clusters; for CodeLink™ 28,949 of 54,841</text>
<text top="579" left="315" width="241" height="9" font="font4" id="p1_t97" reading_order_no="94" segment_no="9" tag_type="text">(52.78%); for Agilent 32,402 of 44,290 (73.15%); and for the<i>COL1A1</i></text>
<text top="590" left="315" width="241" height="9" font="font4" id="p1_t98" reading_order_no="95" segment_no="9" tag_type="text">20 k brk 12,055 of 19,959 (60.4%). Overlay of the transcript</text>
<text top="602" left="315" width="240" height="9" font="font4" id="p1_t99" reading_order_no="96" segment_no="9" tag_type="text">coverage of each microarray demonstrated that each platform<i>SCGB2A2</i></text>
<text top="614" left="315" width="241" height="9" font="font4" id="p1_t100" reading_order_no="97" segment_no="9" tag_type="text">contributed a set of unique genes as well as those common to</text>
<text top="626" left="315" width="240" height="9" font="font4" id="p1_t101" reading_order_no="98" segment_no="9" tag_type="text">other platforms, justifying the use of more than one microarray<i>SELE</i></text>
<text top="637" left="315" width="240" height="9" font="font4" id="p1_t102" reading_order_no="99" segment_no="9" tag_type="text">platform. (Full annotation of each microarray platform to HTR</text>
<text top="649" left="315" width="240" height="9" font="font4" id="p1_t103" reading_order_no="100" segment_no="9" tag_type="text">clusters is available as Additional file 5) The microarray fea-<i>IL8</i></text>
<text top="661" left="315" width="240" height="9" font="font4" id="p1_t104" reading_order_no="101" segment_no="9" tag_type="text">tures of all four platforms provided a total coverage of 26,103</text>
<text top="673" left="315" width="240" height="9" font="font4" id="p1_t105" reading_order_no="102" segment_no="9" tag_type="text">HTRs, and 6,342 out of 6,553 (96.8%) of the differentially<b>Establishing a microarray validated transcriptome</b></text>
<text top="684" left="315" width="240" height="9" font="font4" id="p1_t106" reading_order_no="103" segment_no="9" tag_type="text">expressed transcripts obtained by MPSS were represented</text>
<text top="696" left="315" width="191" height="9" font="font4" id="p1_t107" reading_order_no="104" segment_no="9" tag_type="text">on one or more of these genome-wide platforms.</text>
</page>
</pdf2xml>
